Dr Steven Pipe delves into the economic burden associated with Hemophilia B treatment, including costs and payer considerations.

Distinctions between unbranded biologics, branded biologics, and biosimilars are explored by David Charles, MD.

Arwen Podesta, MD; Timothy Aungst, PharmD; and Scottle Whittle, MD, explain the considerations they think about before using or prescribing DTx and PDTs.

A distinguished panel provides an overview of what digital therapeutics (DTx) and prescription digital therapeutics (PDTs) are and how they’re used in behavioral health treatment.

Steven Pipe, MD, defines Hemophilia B and its standard of care.

In this second part of a two-part video series, Nathan Allen, Senior Vice President – Healthcare Provider Solutions at Firstsource, discusses Medicaid Redetermination for those who are Medicaid members, but are deemed to lose their coverage due to the upcoming expiration of COVID-19’s Public Health Emergency. Allen set a scope on Medicaid populations in rural settings and how they could be affected. However, there is hope through tech-based solutions and a proposed rule by CMS to prevent facility closures and preserve access to care for all affected Medicaid populations.

Nathan Allen, Senior Vice President – Healthcare Provider Solutions at Firstsource, discusses Medicaid Redetermination for those who are Medicaid members, but are deemed to lose their coverage due to the upcoming expiration of COVID-19’s Public Health Emergency.

Dr David Charles, MD, opens a discussion surrounding the increasing usage and unique characteristics of biologics.

MHE spoke with Matt Parker, vice president of Products at Kyruus and HealthSparq, about the recent price transparency rules that recently went into effect and how they can bring efficiency into care.